Vicore Pharma Holding AB
No SEC Form 4 filings for $VCRE in the last 30 days.
See all $VCRE insider activity →U.S. stock futures were mixed. Evolution Metals & Technologies (EMAT) fell in pre-market after reporting Q2 losses of 2 cents per share, beating consensus of 3 cents, but sales of $1.636M missed $2.100M; shares fell 5.5% to $2.86. Barfresh (BRFH) dropped 24% after weaker Q2 results and lowered FY26 sales guidance. Snap (SNAP) fell about 15% to $4.62.
Citi Issuer Services (Citibank N.A.) was appointed depositary bank for Vicore Pharma Holding AB’s sponsored Level 2 ADR program. Vicore Pharma ADRs trade on Nasdaq Capital Market under VCRE, with each ADS representing 10 ordinary shares; ordinary shares trade on Nasdaq Stockholm as VICO. Citi cited its ADR services and global network.
Vicore Pharma said its ADSs will begin trading in the U.S. on Nasdaq after the SEC declared its Form 20-F registration effective and Nasdaq approved the listing. The Nasdaq U.S. listing is secondary and involves no capital raise or new shares; Citi is the depositary bank. Vicore Pharma trades on Nasdaq Stockholm as VICO and Nasdaq U.S. as VCRE.
Over the past 7 days, alphai's AI scored 1 news story mentioning VCRE (Vicore Pharma Holding AB). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent VCRE coverage spans market movers, corporate actions and financial news.
This appears to be momentum mean reversion rather than new information.
The appointment is a structural market-access update for Vicore’s ADRs; it can modestly affect liquidity/visibility but is not a fundamental operating change.
Secondary Nasdaq US ADS listing should improve US access/liquidity, but the company states no capital raise or new shares were issued.
alphai scores every news story that mentions VCRE with an AI model for sentiment and relevance, and aggregates insider trades from Vicore Pharma Holding AB's SEC EDGAR Form 4 filings. Figures refresh continuously.
U.S. stock futures were mixed. Evolution Metals & Technologies (EMAT) fell in pre-market after reporting Q2 losses of 2 cents per share, beating consensus of 3 cents, but sales of $1.636M missed $2.100M; shares fell 5.5% to $2.86. Barfresh (BRFH) dropped 24% after weaker Q2 results and lowered FY26 sales guidance. Snap (SNAP) fell about 15% to $4.62.
3 min readCiti Issuer Services (Citibank N.A.) was appointed depositary bank for Vicore Pharma Holding AB’s sponsored Level 2 ADR program. Vicore Pharma ADRs trade on Nasdaq Capital Market under VCRE, with each ADS representing 10 ordinary shares; ordinary shares trade on Nasdaq Stockholm as VICO. Citi cited its ADR services and global network.
2 min readVicore Pharma said its ADSs will begin trading in the U.S. on Nasdaq after the SEC declared its Form 20-F registration effective and Nasdaq approved the listing. The Nasdaq U.S. listing is secondary and involves no capital raise or new shares; Citi is the depositary bank. Vicore Pharma trades on Nasdaq Stockholm as VICO and Nasdaq U.S. as VCRE.
2 min read
